OCUL Ocular Therapeutix, Inc.

10.12
+0.13  (1.3%)
Previous Close 9.99
Open 9.90
Price To book 3.99
Market Cap 251.78M
Shares 24,879,000
Volume 1,665,672
Short Ratio 5.23
Av. Daily Volume 1,077,370

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmission announced January 23, 2017.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. Why Ocular Therapeutix Inc Jumped Higher Today
  2. Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences
  3. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State
  4. ETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017
  5. Ocular Therapeutics Sinks Following Secondary Offering
  6. Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock
  7. Ocular Therapeutix, Inc. Announces Public Offering of Common Stock
  8. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events
  9. Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
  10. ETFs with exposure to Ocular Therapeutix, Inc. : January 9, 2017
  11. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  12. Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
  13. Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™
  14. Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™
  15. ETFs with exposure to Ocular Therapeutix, Inc. : December 30, 2016
  16. 7 Key FDA Decisions and Catalysts Expected in January and February
  17. How Ocular Therapeutix Inc (OCUL) Stacks Up Against Its Peers
  18. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events
  19. ETFs with exposure to Ocular Therapeutix, Inc. : December 8, 2016
  20. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State